Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis

头孢唑林 医学 菌血症 内科学 中止 优势比 置信区间 金黄色葡萄球菌 不利影响 葡萄球菌感染 科克伦图书馆 抗生素 外科 微生物学 细菌 生物 遗传学
作者
Changcheng Shi,Yubo Xiao,Qi Zhang,Qingyu Li,Fei Wang,Jing Wu,Nengming Lin
出处
期刊:BMC Infectious Diseases [BioMed Central]
卷期号:18 (1) 被引量:41
标识
DOI:10.1186/s12879-018-3418-9
摘要

Antistaphylococcal penicillins (ASPs) and cefazolin have become the most frequent choices for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) infections. However, the best therapeutic agent to treat MSSA bacteremia remains to be established. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of these two regimens for the treatment of MSSA bacteremia. PubMed, EMBASE and the Cochrane Library from inception to February 2018 were searched. The primary outcome was mortality. The secondary outcomes included treatment failure, recurrence of bacteremia, adverse effects (AEs) and discontinuation due to AEs. Data were extracted and pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. A total of ten observational studies met the inclusion criteria. The results indicate that compared to ASPs, cefazolin was associated with significant reduction in mortality (OR, 0.69; 95% CI, 0.58 to 0.82; I2 = 3.4%) and clinical failure (OR, 0.56; 95% CI, 0.37 to 0.85; I2 = 44.9%) without increasing the recurrence of bacteremia (OR, 1.12; 95% CI, 0.94 to 1.34; I2 = 0%). There were no significant differences for the risk of anaphylaxis (OR, 0.91; 95% CI, 0.36 to 2.99; I2 = 0%) or hematotoxicity (OR, 0.56; 95% CI, 0.17 to 1.88; I2 = 0%). However, nephrotoxicity (OR, 0.36; 95% CI, 0.16 to 0.81; I2 = 0%) and hepatotoxicity (OR, 0.12; 95% CI, 0.04 to 0.41; I2 = 0%) were significantly lower in the cefazolin group. Moreover, cefazolin was associated with lower probability of discontinuation due to AEs compared with the ASPs (OR, 0.24; 95% CI, 0.12 to 0.48; I2 = 18%). The results of present study favor the application of cefazolin and should be regarded as important evidence to help make clinical decisions in choosing a treatment option for treating MSSA bacteremia.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1111发布了新的文献求助10
1秒前
charry完成签到,获得积分10
1秒前
小包包了包完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
DJ完成签到 ,获得积分10
2秒前
慕青的应助被瓜瓜采纳,获得10
2秒前
hu完成签到 ,获得积分10
3秒前
结实的胡萝卜完成签到,获得积分10
3秒前
生化环材的生化环材完成签到,获得积分10
3秒前
乔凌云完成签到 ,获得积分10
3秒前
怡然的凌兰完成签到,获得积分10
3秒前
3秒前
平淡的惜芹完成签到,获得积分10
4秒前
CodeCraft的应助被星空采纳,获得10
4秒前
深情安青的应助被海洋蝌蚪采纳,获得10
4秒前
热情小凡完成签到,获得积分10
4秒前
jklwss完成签到,获得积分10
4秒前
swent_66完成签到,获得积分10
4秒前
4秒前
jg完成签到,获得积分10
4秒前
4秒前
zhabgyyy完成签到,获得积分10
5秒前
5秒前
5秒前
12发布了新的文献求助10
5秒前
hjabao完成签到,获得积分10
5秒前
丘比特的应助被慕念采纳,获得10
5秒前
6秒前
八倍速生活完成签到,获得积分10
6秒前
QDU的应助被吾吾采纳,获得10
6秒前
7秒前
7秒前
顺心的曲奇完成签到,获得积分10
8秒前
安静破茧完成签到,获得积分10
8秒前
便便民工完成签到,获得积分20
8秒前
9秒前
光亮向真发布了新的文献求助10
9秒前
lkk完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162